Shouki Bazarbashi
Overview
Explore the profile of Shouki Bazarbashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aseafan M, Alfakeeh A, Tashkandi E, Mahrous M, Alghamdi M, Alshamsan B, et al.
BMC Cancer
. 2025 Jan;
25(1):7.
PMID: 39754118
Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited treatment options yielding poor outcomes. This study aimed to evaluate the real-world clinical characteristics, treatment patterns,...
2.
Bazarbashi S, El Zawahry H, Owaidah T, AlBader M, Warsi A, Marashi M, et al.
J Blood Med
. 2024 Apr;
15:171-189.
PMID: 38686358
Venous thromboembolism is a leading cause of morbidity and mortality in patients with active cancer who require anticoagulation treatment. Choice of anticoagulant is based on careful balancing of the risks...
3.
Bazarbashi S, Alkhatib R, Aseafan M, Tuleimat Y, Abdel-Aziz N, Mahrous M, et al.
JCO Glob Oncol
. 2024 Mar;
10:e2300461.
PMID: 38484194
Purpose: Metastatic colorectal cancer (mCRC) is a significant global health burden. This retrospective study compared the effectiveness of trifluridine/tipiracil (FTD/TPI), regorafenib, and chemotherapy rechallenge for third-line mCRC treatment. Materials And...
4.
Alolyan A, Alshammari K, Arabi M, Alshehri A, Alsuhaibani H, Ibnshamsah F, et al.
J Hepatocell Carcinoma
. 2024 Feb;
11:349-362.
PMID: 38385059
Hepatocellular carcinoma (HCC) is the sixth most common type of cancer in the world associated with high morbidity and mortality. Despite being a significant healthcare burden there is limited information...
5.
Bazarbashi S, Aseafan M, Elshenawy M, Alzahrani A, Aljubran A, Almugbel F, et al.
Cureus
. 2024 Feb;
16(1):e52656.
PMID: 38380191
Introduction: Biliary tract cancers (BTCs), characterized by poor prognosis and limited treatment options, are increasingly prevalent malignancies with a five-year survival rate of less than 20% for advanced-stage disease. The...
6.
Bazarbashi S, Aseafan M, Elgazzar T, Alkhayat M, Alghabban A, Abdelgawad M, et al.
BMC Endocr Disord
. 2023 Apr;
23(1):74.
PMID: 37029347
Background: Gastroenteropancreatic Neuroendocrine tumors (GEP-NET) are rare neoplasms with limited reported data from the Middle East. Our study aims to report the clinicopathological feature, treatment patterns, and survival outcomes of...
7.
Alshamsan B, Aseafan M, Badran A, Shaheen A, Elshenawy M, Bazarbashi S, et al.
Mol Clin Oncol
. 2023 Feb;
18(3):17.
PMID: 36798464
Small bowel adenocarcinoma (SBA) is an extremely rare cancer type. In the present study, the patient characteristics and clinical outcomes of patients diagnosed and treated for SBA at a single...
8.
AlSheef M, Bazarbashi S, Warsi A, Alfraih F, Almoomen A, Osman A, et al.
TH Open
. 2023 Feb;
7(1):e14-e29.
PMID: 36751300
Cancer is a well-known risk factor of preventable thromboembolic disease. This study aims to provide guidance on the prevention and management of cancer-associated thrombosis (CT) that tailors prophylactic and therapeutic...
9.
Bazarbashi S, Alzahrani A, Aljubran A, Elshenawy M, Gad A, Maraiki F, et al.
Oncologist
. 2023 Jan;
28(5):e254-e262.
PMID: 36648325
Background: Tyrosine kinase inhibitors remain a cornerstone in managing metastatic clear cell renal cell carcinoma (RCC). The 4 weeks on/2 weeks off intermittent sunitinib schedule could result in rebound angiogenesis...
10.
Elashwah A, Alsuhaibani A, Abduljabbar A, Alsanea N, Alhomoud S, Ashari L, et al.
J Gastrointest Cancer
. 2022 Dec;
54(3):927-936.
PMID: 36525233
Purpose: Evaluating the outcome of pre-operative simultaneous integrated boost volumetric modulated arc therapy (SIB-VMAT) concomitant with capecitabine in patients diagnosed with locally advanced rectal cancer (LARC) at King Faisal Specialist...